汇丰环球研究报告表示，翰森制药(03692.HK) 今年上半年业绩强劲，收入及盈利按年分别增长14%及15%，超出该行预测。汇研预计，公司创新产品线在今个财年将达到82%；亦预计凭借公司强大的临床阶段资产，将达成更多业务发展交易。汇研仍认为翰森制药估值具吸引力，考虑到其高比例创新药及进一步业务发展的上升潜力。汇研预计，公司今年上半年业务发展收入为17亿元人民币(下同)，包括来自葛兰素史克(GSK)...
Source Link汇丰环球研究报告表示，翰森制药(03692.HK) 今年上半年业绩强劲，收入及盈利按年分别增长14%及15%，超出该行预测。汇研预计，公司创新产品线在今个财年将达到82%；亦预计凭借公司强大的临床阶段资产，将达成更多业务发展交易。汇研仍认为翰森制药估值具吸引力，考虑到其高比例创新药及进一步业务发展的上升潜力。汇研预计，公司今年上半年业务发展收入为17亿元人民币(下同)，包括来自葛兰素史克(GSK)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.